Details

Target Discovery and Validation

Methods and Strategies for Drug Discovery
Methods & Principles in Medicinal Chemistry 1. Aufl.

von: Alleyn T. Plowright, Raimund Mannhold, Helmut Buschmann, Jörg Holenz
151,99 €
Verlag:	Wiley-VCH
Format:	PDF
Veröffentl.:	02.12.2019
ISBN/EAN:	9783527818259
Sprache:	englisch
Anzahl Seiten:	400

In den Warenkorb

Als Gutschein

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

Titelbeschreibung

The modern drug developers? guide for making informed choices among the diverse target identification methods Target Discovery and Validation: Methods and Strategies for Drug Discovery offers a hands-on review of the modern technologies for drug target identification and validation. With contributions from noted industry and academic experts, the book addresses the most recent chemical, biological, and computational methods. Additionally, the book highlights techologies that are applicable to ?difficult? targets and drugs directed at multiple targets, including chemoproteomics, activity-based protein profiling, pathway mapping, genome-wide association studies, and array-based profiling. Throughout, the authors highlight a range of diverse approaches, and target validation studies reveal how these methods can support academic and drug discovery scientists in their target discovery and validation research. This resource: -Offers a guide to identifying and validating targets, a key enabling technology without which no new drug development is possible -Presents the information needed for choosing the appropriate assay method from the ever-growing range of available options -Provides practical examples from recent drug development projects, e. g. in kinase inhibitor profiling Written for medicinal chemists, pharmaceutical professionals, biochemists, biotechnology professionals, and pharmaceutical chemists, Target Discovery and Validation explores the current methods for the identification and validation of drug targets in one comrpehensive volume. It also includes numerous practical examples.

Inhaltsverzeichnis

Preface xiii A Personal Foreword xvii 1 Chemical Strategies for Evaluating New Drug Targets 1 Adrian J. Carter, Raina Seupel, Paul E. Brennan, Michael Sundström, Andrea Introini, and Anke Mueller-Fahrnow 1.1 Introduction 1 1.2 Use Cases and Case Studies for Chemogenomic Compounds and Chemical Probes 5 1.2.1 Chemogenomic Libraries 5 1.2.2 Inactive Control 6 1.2.3 Use of Biological Target Panels and Profiling 8 1.3 Development of Chemical Probes 10 1.3.1 From BIX01294 to EPZ035544: Development and Improvement of G9a/GLP Inhibitors 10 1.3.2 Development of BRD9 Inhibitors 12 1.4 Compound-Based Target Evaluation with Patient-Derived Cells 14 1.4.1 Compound-Based Target Evaluation 14 1.4.2 Patient-Derived Cell Assays 16 1.4.3 Target Evaluation Approach 16 1.4.4 Case Story: Inflammatory Bowel Disease (IBD) Tissue Platform 18 1.5 Summary and Outlook 19 References 20 2 Affinity-Based Chemoproteomics for Target Identification 25 Annika Jenmalm Jensen and Ivan Cornella Taracido 2.1 Introduction 25 2.2 Small Molecule Phenotypic Mechanism of Action Elucidation 29 2.3 Quantitative High-Resolution Mass Spectrometry as a Protein Detection Read-Out 30 2.4 In-Lysate Affinity-Based Chemical Proteomics 33 2.4.1 Design of the Affinity Probe 34 2.4.2 General Experimental Pulldown Workflow 36 2.4.3 Limitations 38 2.5 In-Cell Light-Activated Affinity-Based Chemoproteomics 39 2.5.1 Design of the Reactive Photoaffinity Probe (PAL Probe) 40 2.5.2 General Experimental Workflow 40 2.5.3 Limitations 43 2.6 Target Validation and Mode of Action 43 2.7 Concluding Remarks 45 References 46 3 Activity-Based Protein Profiling 51 Nattawadee Panyain, Cassandra R. Kennedy, Ryan T. Howard, and Edward W. Tate 3.1 Introduction 51 3.2 Activity-Based Probe (ABP) and Affinity-Based Probe (AfBP) Design 53 3.2.1 Warheads (Reactive Groups) 53 3.2.1.1 Electrophilic Warheads 55 3.2.1.2 Photocrosslinking Warheads 55 3.2.2 Reporter Tags 56 3.2.3 Linkers 56 3.2.4 Bioorthogonal Ligation Chemistry 57 3.2.4.1 Staudinger Ligation 58 3.2.4.2 Copper(I)-Catalysed Azide-Alkyne Cycloaddition (CuAAC) 58 3.2.4.3 Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC) 59 3.2.4.4 Diels–Alder Reaction 59 3.3 Chemical Proteomic Workflow 60 3.3.1 Quantitative Proteomics by Mass Spectrometry 61 3.3.1.1 Label-Free Quantification (LFQ) 61 3.3.1.2 Chemical Labelling Quantification 61 3.3.1.3 Metabolic Labelling Quantification 63 3.4 ABPP Applications and Case Studies 63 3.4.1 Case Study 1: Activity-Based Protein Profiling as a Robust Method for Enzyme Identification and Screening in Extremophilic Archaea 65 3.4.2 Case Study 2: Failed Clinical Trial of a Fatty Acid Amide Hydrolase (FAAH) Inhibitor 68 3.4.3 Case Study 3: Target Identification of Small Molecule Inhibitors 71 3.4.3.1 New Target Profiling for Sulforaphane 71 3.4.3.2 Profiling USP Inhibitors in Human Cell Lines as Potential Therapeutic Molecules 73 3.4.4 Case Study 4: Fragment-Based Ligand Discovery Aided by Photoaffinity Labelling 74 3.4.5 Case Study 5: Quenched Fluorescent Activity-Based Probe (qABP) Design and Application in Protein Localization 80 3.5 Summary 82 References 83 4 Kinobeads: A Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery 97 Maria Reinecke, Stephanie Heinzlmeir, Mathias Wilhelm, Guillaume Médard, Susan Klaeger, and Bernhard Kuster 4.1 Kinase Inhibitor Target Deconvolution Using Chemical Proteomics 97 4.1.1 Polypharmacology of Small Molecule Kinase Inhibitors 97 4.1.2 Chemoproteomic Profiling of Kinase Inhibitors 100 4.1.3 Tips and Tricks Regarding Chemoproteomic Assay Development 103 4.2 Detailed Kinobeads Protocol 105 4.2.1 Cell or Tissue Lysate 107 4.2.2 Affinity Matrices 107 4.2.3 Kinobeads Competition Assay 110 4.2.4 Mass Spectrometry 111 4.2.5 Peptide and Protein Identification and Quantification 112 4.2.6 Data Analysis 112 4.3 Application Examples for Kinobeads 113 4.3.1 Expanding the Target Space of Kinobeads 113 4.3.2 Target Space Deconvolution of Small Molecule Kinase Inhibitors 116 4.3.3 Opportunities Arising from Inhibitor Polypharmacology: Drug Repositioning 120 4.3.4 Chemoproteomic-Guided Medicinal Chemistry 121 4.4 Kinobeads, Inhibitors, and Drug Discovery: Where are We Heading? 123 4.4.1 What is a Good Drug? 123 4.4.2 How Can We Discover New Drugs in the Future? 124 4.4.3 The Yin and Yang of Chemoproteomic-Guided Drug Discovery 124 Acknowledgments 125 References 125 5 Label-Free Techniques for Target Discovery and Validation 131 Daniel Martinez Molina and Michael Dabrowski 5.1 Introduction 131 5.2 CETSA: How It All Began 132 5.3 The CETSA Formats 136 5.3.1 CETSA Classics 136 5.3.2 CETSA HT 138 5.3.3 CETSA MS 140 5.4 Target Discovery 142 5.4.1 Generation of Active Hit Molecules 142 5.4.2 Tool Generation (Small Screens to Identify Tool Compounds) 143 5.4.3 Target Classes That are In and Out of Scope and Difficult Targets 143 5.4.4 Focused or Iterative Library Screening 144 5.4.5 Fragment Library Screening 144 5.4.6 Hit Confirmation 145 5.4.7 Phenotypic Hit Deconvolution to Discover Targets 145 5.5 Target Validation 147 5.5.1 Binding Modes 147 5.5.2 Selectivity, Specificity, and Safety 148 5.5.3 Translation Bench to Bedside (via Animals) 149 5.6 Conclusion 150 References 151 6 Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine 153 Lauren Drowley and Martin Armstrong 6.1 Introduction: the Challenge 153 6.2 Genetics to Date in Drug Discovery 154 6.3 Genetic Strategies for Target Discovery 156 6.3.1 GWAS 158 6.3.2 Rare Disease Genetics 160 6.3.2.1 Rare Mutation→Rare Disease Drug Discovery 161 6.3.2.2 Rare Mutation→Common Disease Drug Discovery 161 6.3.3 Somatic Mutations 162 6.3.4 Analytical Approaches 163 6.4 Functional Validation 164 6.4.1 Prioritization of Putative Mutations 165 6.4.2 Determining Functional Consequence of Mutation 165 6.4.2.1 Publicly Available Data 165 6.4.2.2 Systems Biology 166 6.4.2.3 Model Systems: ‘The Tissue is the Issue’ 168 6.4.3 Druggability: From Validation of a Gene to a Druggable Target 169 6.5 Forward-Looking Perspectives 170 6.5.1 Molecular Taxonomy of Disease 171 6.5.2 Precision Medicine 171 6.5.3 Data Integration 172 6.6 Conclusion 173 References 173 7 Elucidating Target Biology and Drug Mechanism of Action Across Human Cell-Based Model Systems 179 John C. Dawson and Neil O. Carragher 7.1 Introduction 179 7.2 Advances in Human Cell-Based Model Development 182 7.2.1 Next-Generation Sequencing (NGS) 183 7.2.2 CRISPR Genome Editing 184 7.2.3 Induced Pluripotent Stem Cell Biology 184 7.2.4 3D Cell and Organoid Models 185 7.2.5 Microfluidic and Organ-on-a-Chip Devices 186 7.2.6 In Vivo Imaging 188 7.2.7 High-Content Imaging 190 7.3 Multiparametric High-Content Phenotypic Profiling of Target Biology and Drug Mechanism of Action 191 7.3.1 High-Content Cell Painting in Functional Genomics 193 7.3.2 Integration of Multiparametric High-Content Imaging with Chemoinformatics 195 7.3.3 Guiding Chemical Design and Target Selectivity from Multiparametric High-Content Analysis 195 7.4 Target-Annotated Compound Libraries for Phenotypic Screening and MOA Determination 196 7.5 Quantitative Pathway Profiling Across New Model Systems 197 7.5.1 Pathway Profiling at the Gene Transcription Level 198 7.5.2 Dynamic Post-Translational Pathway Profiling Across Dose–Response and Time-Series Studies 199 7.6 Conclusions 202 References 203 8 Cell Biology Methods in Target Validation 211 Manfred Koegl and Simon Wöhrle 8.1 Introduction 211 8.2 Biomarkers 211 8.2.1 Direct Target Engagement Biomarkers 212 8.2.2 Indirect Target Engagement Biomarkers and Pathway Biomarkers 213 8.2.3 Response Biomarkers 214 8.2.4 Correlation of Biomarkers 214 8.3 Direct Evidence to Show That Modulation of a Target Leads to a Cellular Response 219 8.4 Direct Evidence That Target Modulation is Responsible for Cellular Responses by Mutations Conferring Sensitivity to Existing Drugs 219 8.4.1 The ‘Bump-and-Hole’ Approach to Generate Sensitivity to Small Molecule Inhibitors 219 8.4.2 Chemogenomic Approaches for Inducible Degradation of Protein Targets 222 8.5 Resistance Conferring Mutations 226 References 229 9 Genetic Manipulation/Modulation for Target Discovery and Validation 233 Christophe Lanneau, Georges Kalouche, Xinming Cai, Francois Lo-Presti, and Christoph Potting 9.1 Introduction 233 9.2 Overview of the Development of Leading Genetic Manipulation Technologies 234 9.2.1 RNAi, ZFNs, and TALENs 234 9.2.2 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 237 9.3 Considerations for Designing and Interpreting CRISPR Experiments 238 9.3.1 Methodological Considerations for Genetic Manipulation by the CRISPR/Cas Technology 238 9.3.2 Choosing a Cellular Model: Biological and Genomic Aspects 239 9.3.3 gRNA Design 242 9.3.3.1 Identification of Target Locations 242 9.3.3.2 Selection of Spacer Sequences 245 9.3.3.3 Predictive Tools 247 9.3.4 Successful Application of the CRISPR/Cas Technology 249 9.3.4.1 Delivering CRISPR Reagents to Target Cells 249 9.3.4.2 Check for Anticipated Knockout/Knock-In 252 9.4 Further Developments of the CRISPR/Cas Technology Facilitates Additional Modes of Genetic Perturbation 253 9.4.1 CRISPRi 253 9.4.2 CRISPRa 253 9.4.3 Base Editing 254 9.5 The CRISPR/Cas Technology in Target Discovery and Validation 254 9.5.1 CRISPR/Cas Technology for Early Target Validation 254 9.5.2 CRISPR Screens and Use for Target Discovery 255 9.5.3 CRISPR Screens: General Principle and Considerations 256 9.5.4 Selected Examples of Target Discovery Using CRISPR Screens to Illustrate the Breadth of Applications 258 9.6 Application of CRISPR Genome Editing in Immunology Studies 260 9.7 Concluding Remarks 262 References 263 10 Computational Approaches for Target Inference 277 Gerhard Hessler, Christoph Grebner, and Hans Matter 10.1 Introduction 277 10.2 Data Annotation for Target Identification 278 10.3 In Silico Methods for Target Identification 280 10.3.1 2D Similarity Methods for Target Inference 283 10.3.2 3D Similarity Methods for Target Inference 289 10.3.3 Fragment-Based Approaches 290 10.3.4 QSAR Models and Machine Learning 292 10.3.5 Experimentally Derived Molecular Descriptors 297 10.3.6 Structure-Based Screening 299 10.3.7 Protein–Protein and Ligand–Target Networks 302 10.4 Practical Considerations 304 10.5 Conclusion 307 References 308 11 Bioinformatic Approaches in the Understanding of Mechanism of Action (MoA) 323 Maria-Anna Trapotsi, Ian Barrett, Ola Engkvist, and Andreas Bender 11.1 Bioinformatics: Introduction 323 11.1.1 Some Definitions: Mechanism Versus Mode of Action 323 11.1.2 Importance of MoA and Target Prediction in the Drug Discovery Process 324 11.1.3 Different Levels of Information in Mechanism of Action and Target Prediction 325 11.2 Transcriptomics Data and Databases 326 11.2.1 Biological Background of the Transcription Process 326 11.2.2 Connectivity Map: CMap 327 11.2.2.1 Applications of CMap in MoA Deconvolution 328 11.2.3 Library of Integrated Network-Based Cellular Signatures (LINCS) 331 11.2.3.1 LINCS L1000 Data Exploration 332 11.2.3.2 Applications of L1000 Data in MoA Understanding 333 11.3 Pathway Data and Databases 339 11.3.1 What is a Pathway? 339 11.3.2 Process of Pathway Analysis 341 11.3.3 Pathways in the Understanding of MoA 345 11.3.3.1 Methodology 1: MoA Analysis by Annotating Predicted Compounds’ Targets with Pathways 345 11.3.4 Combination of Gene Expression and Pathway Data 346 11.3.4.1 Methodology 2: Construction of Drug Networks (DNs) with Gene Expression Data and Pathway Annotations 346 11.3.4.2 Methodology 3: Link Drug Target and Pathway Activation to Understand MoA 347 11.4 Image-Based Data 348 11.4.1 Image Data and Where to Extract Them From 348 11.4.2 Application of Image-Based Data in Target Prediction and Better Understanding of MoA 350 11.4.2.1 Methodology 1: Clustering of Compounds Based on Cell Morphology 350 11.4.2.2 Methodology 2: Use of Image-Based Data in the Development of a Cell Morphology Database That Can Facilitate Drug Target Identification 350 11.4.2.3 Methodology 3: Use of Image Data in Drug Repositioning and Biological Activity Prediction 353 11.4.2.4 Methodology 4: Association of Genes with Context-Dependent Morphology Alterations from Cells Exposed to Chemical or Genetic Perturbations for MoA Elucidation 354 11.5 Conclusions 357 Acknowledgement 357 References 357 Index 365

Autorenportrait

Alleyn Plowright obtained his PhD in organic chemistry with Professor Gerald Pattenden at the University of Nottingham, UK in 1999, and continued with postdoctoral studies in chemical biology with Professor Andrew Myers at Harvard University, USA. In 2002, he joined AstraZeneca and in 2008 he became Associate Director Medicinal Chemistry leading the Lead Optimisation section driving new programs to the clinic. In 2012, Dr. Alleyn took on the role of Senior Principal Scientist and Project Leader in the Cardiovascular and Metabolic Diseases Innovative Medicines unit leading multidisciplinary research, including phenotypic screening and driving new projects into and through the drug project portfolio. In 2017 he moved to Sanofi, taking on the position as Head Integrated Drug Discovery Germany leading a cross-disciplinary research unit driving projects from target validation through to pre-clinical development. He has been instrumental in delivering a number of compounds into the clinic, including two compounds currently in phase 2 clinical trials, and has authored more than 50 publications and patents.